This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.
Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.
Here's Why You Should Hold on to Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails
by Zacks Equity Research
Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.
Penumbra and Mesa Labs have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra and Mesa Labs are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovator of neurovascular stroke technologies with 980% EPS growth is a buying opportunity
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Encompass Health (EHC) Up 41% in a Year: More Room for Growth?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Buy These 3 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Penumbra (PEN), Strategic Education (STRA) and Huron (HURN) are poised to gain.
Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Factors That Make Molina Healthcare (MOH) an Attractive Bet Now
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on a growing customer base, acquisitions and solid cash reserves.
Wall Street Analysts Believe Penumbra (PEN) Could Rally 27.69%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 27.7% upside potential for Penumbra (PEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Is Penumbra (PEN) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.
Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.
Here's Why You Should Invest in Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.
TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant
by Zacks Equity Research
TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.
Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind
by Zacks Equity Research
Phibro (PAHC) input costs continue to be high as a result of sustained inflation.
Neogen (NEOG) Introduces New Genomic Data Management Tool
by Zacks Equity Research
Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.